Alliance strengthens commercial readiness of AGROBODY platform as Biotalys prepares next phase of growth

Biotalys (Euronext: BTLS), an agricultural technology company developing next-generation protein-based biocontrol solutions, has entered into a strategic partnership with 21st.BIO, a Danish leader in precision fermentation, to accelerate and scale the production of its AGROBODY biocontrol portfolio.

Under the agreement, Biotalys will leverage 21st.BIO’s industry-leading precision fermentation platform to manufacture its protein-based agricultural products at commercially competitive costs. The collaboration is designed to expand process development options and support efficient, large-scale production as Biotalys advances toward commercialization.

21st.BIO’s platform is powered by production strains refined over more than four decades and validated across broad commercial use. Parts of the technology are licensed from Novonesis, and the partnership integrates 21st.BIO’s capabilities with earlier development work conducted by Biotalys and Novonesis, strengthening the industrial foundation of Biotalys’ pipeline.

“This partnership marks an important strategic step in reinforcing the technical backbone of our AGROBODY platform,” said Kevin Helash, CEO of Biotalys. “By combining 21st.BIO’s proven fermentation expertise with our innovation in protein-based biocontrols, we are building the manufacturing capabilities needed to support a growing and differentiated product portfolio.”

Helash added, “Our collaboration with Novonesis—and its relationship to 21st.BIO—was instrumental in enabling this next phase as we advance EVOCA™ NG and other pipeline products toward commercialization.”

Thomas Schmidt, co-founder and CEO of 21st.BIO, commented: “21st.BIO was founded to translate promising lab-scale innovation into reliable, cost-effective industrial production—quickly and with reduced risk. We are proud to help Biotalys lower production costs and accelerate time to market, ensuring that protein-based biocontrols such as EVOCA NG become a sustainable and economically viable option for growers worldwide.”

As part of the transition to the new agreement, Biotalys and Novonesis will conclude their collaboration. Biotalys is currently engaging with manufacturing and distribution partners globally to finalize its commercialization strategy and expects to have key arrangements in place well ahead of the planned launch of EVOCA NG, subject to regulatory approvals currently anticipated for 2028–29 in the U.S. and 2029–30 in the E.U.

Funding Update

Biotalys confirmed that its cash runway extends into May 2026, consistent with prior guidance. To support the next phase of development and commercialization of EVOCA NG, as well as continued advancement of its broader AGROBODY portfolio, the company is evaluating additional financing options, including potential equity investments from institutional investors.